https://www.marketscreener.com/quote/stock/GALAPAGOS-NV-6464/news/Galapagos-N-V-Galapagos-demonstrates-early-clinical-activity-with-SIK2-3-inhibition-in-inflamm-35864159/?utm_source=telegram&utm_medium=social&utm_campaign=share